Market Insights

The global mRNA Vaccine and Therapeutics market is expected to reach USD 2911.8 million in 2027 from USD 587.5 million in 2020 and is projected to grow at a CAGR value of over 28.4% during the forecast period.

mRNA is the intermediary stage between translating protein-encoding DNA and making proteins by ribosomes in the cytoplasm. Currently, virally derived, self-amplifying RNA and non-replicating mRNA are the two types of RNA being studied as vaccines. mRNA vaccines have been a promising alternative to conventional vaccine methodologies owing to their safe administration, the potential for low-cost manufacture, capacity for rapid development, and high potency. Over the last few decades, there has been a focus on RNA-based technologies for developing therapeutic vaccines, as mRNA vaccines are highly beneficial in fighting against viral diseases, infections, and cancer.

Key Market Drivers and Restraints

Key factors comprising drivers and restraints of the global mRNA Vaccine and Therapeutics market are included here. It also consists of the elements that can act as challenges and opportunities in the global market.

The lack of stability of RNA molecules may hamper the growth of the market

mRNA is highly prone to degradation. In vivo, naked RNA molecules are volatile, with the enzyme RNases ready to degrade extracellular RNA. The expression effect is guaranteed by stabilizing the mRNA existence, which requires designing the delivery methods to protect the mRNA from degradation and facilitate its uptake in the cells. In addition, the mRNA vaccines need to be stored at ultracold storage conditions to avoid degradation leading to less effective immunity.

North America to dominate the global market.

The global mRNA Vaccine and Therapeutics market Regionally encompasses six regions covering all important markets. Credence Research provides a complete vision of noticeable areas of the global market. Based on the region, North America accounted for the largest share in the global market, with over 40% share in 2020.

Self-amplifying mRNA-based Vaccines to lead mRNA vaccine and therapeutics market

Self-amplifying mRNA-based vaccines offer potential advantages as in the cell, before producing proteins, they generate several copies of it as they contain viral replicase enzyme. Owing to this property, self-amplifying mRNA vaccines express more antigens and are more immunogenic. This causes tremendously vigorous immune responses making it more efficient than other mRNA vaccines.

Infectious diseases remain in the top position in the global market in terms of Application.

The growing prevalence of infectious diseases is leading to a huge socioeconomic burden on countries across the world. To overcome such a burden, there is an increase in funds from government and non-government organizations for the development of mRNA vaccines and therapeutics. In addition, the current covid-19 pandemic situation has tremendously boosted the demand for mRNA-based vaccines, and the demand is expected to surge during the forecast period.

Growing demand from Hospitals and Clinics to boost the market growth

The primary factor boosting the growth of the global market in this region is the rapidly spreading infection caused by a coronavirus. In addition to this, the growing use of standardized therapeutic cancer mRNA vaccines due to the rise in healthcare expenditure, growing prevalence of cancer, and growing awareness regarding the mRNA vaccines are fueling the overall market growth across hospitals and clinics’ end-user.

1.Preface
1.1.Report Description
1.1.1.Purpose of the Report
1.1.2.Target Audience
1.1.3.USP and Key Offerings
1.2.Research Scope
1.3.Research Methodology
1.3.1.Phase I – Secondary Research
1.3.2.Phase II – Primary Research
1.3.3.Phase III – Expert Panel Review
1.3.4.Approach Adopted
1.3.4.1.Top-Down Approach
1.3.4.2.Bottom-Up Approach
1.3.5.Assumptions
1.4.Market Segmentation

2.Executive Summary
2.1.Market Snapshot: Global mRNA Vaccine and Therapeutics Market

3.Market Dynamics & Factors Analysis
3.1.Introduction
3.1.1. Global mRNA Vaccine and Therapeutics Market Value, 2015-2027, (US$ Mn)
3.2.Market Dynamics
3.2.1.Key Growth Trends
3.2.2.Major Industry Challenges
3.2.3.Key Growth Pockets
3.3.Attractive Investment Proposition,2020
3.3.1.Vaccine Type
3.3.2.Application
3.3.3.End User
3.3.4.Geography
3.4.Porter’s Five Forces Analysis
3.4.1.Threat of New Entrants
3.4.2.Bargaining Power of Buyers/Consumers
3.4.3.Bargaining Power of Suppliers
3.4.4.Threat of Substitute Vaccine Types
3.4.5.Intensity of Competitive Rivalry
3.5.Value Chain Analysis

4.Market Positioning of Key Players, 2020
4.1.Company market share of key players, 2020
4.2.Top 6 Players
4.3.Top 3 Players
4.4.Major Strategies Adopted by Key Players

5.COVID 19 Impact Analysis
5.1.Global mRNA Vaccine and Therapeutics Market Pre Vs Post COVID 19, 2019 – 2027
5.2.Impact on Import & Export
5.3.Impact on Demand & Supply

6.North America
6.1.North America mRNA Vaccine and Therapeutics Market, by Country, 2015-2027(US$ Mn)
6.1.1.U.S.
6.1.2.Canada
6.1.3.Mexico
6.2.North America mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027(US$ Mn)
6.2.1.Overview
6.2.2.Self-amplifying mRNA-based Vaccines
6.2.3.Conventional Non-Amplifying mRNA-Based Vaccines
6.3.North America mRNA Vaccine and Therapeutics Market, by Application, 2015-2027(US$ Mn)
6.3.1.Overview
6.3.2.Cancer
6.3.3.Infectious Disease
6.3.4.Other Applications
6.4.North America mRNA Vaccine and Therapeutics Market, by End User, 2015-2027(US$ Mn)
6.4.1.Overview
6.4.2.Hospitals and Clinics
6.4.3.Research Organizations
6.4.4.Other End Users

7.Europe
7.1.Europe mRNA Vaccine and Therapeutics Market, by Country, 2015-2027(US$ Mn)
7.1.1.UK
7.1.2.France
7.1.3.Germany
7.1.4.Italy
7.1.5.Russia
7.1.6.Spain
7.1.7.Belgium
7.1.8.Netherland
7.1.9.Austria
7.1.10.Sweden
7.1.11.Poland
7.1.12.Denmark
7.1.13.Switzerland
7.1.14.Rest of Europe
7.2.Europe mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027(US$ Mn)
7.2.1.Overview
7.2.2.Self-amplifying mRNA-based Vaccines
7.2.3.Conventional Non-Amplifying mRNA-Based Vaccines
7.3.Europe mRNA Vaccine and Therapeutics Market, by Application, 2015-2027(US$ Mn)
7.3.1.Overview
7.3.2.Cancer
7.3.3.Infectious Disease
7.3.4.Other Applications
7.4.Europe mRNA Vaccine and Therapeutics Market, by End User, 2015-2027(US$ Mn)
7.4.1.Overview
7.4.2.Hospitals and Clinics
7.4.3.Research Organizations
7.4.4.Other End Users

8.Asia Pacific
8.1.Asia Pacific mRNA Vaccine and Therapeutics Market, by Country, 2015-2027(US$ Mn)
8.1.1.China
8.1.2.Japan
8.1.3.South Korea
8.1.4.India
8.1.5.Australia
8.1.6.New Zealand
8.1.7.Taiwan
8.1.8.Southeast Asia
8.1.9.Central Asia
8.1.10.Rest of Asia Pacific
8.2.Asia Pacific mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027(US$ Mn)
8.2.1.Overview
8.2.2.Self-amplifying mRNA-based Vaccines
8.2.3.Conventional Non-Amplifying mRNA-Based Vaccines
8.3.Asia Pacific mRNA Vaccine and Therapeutics Market, by Application, 2015-2027(US$ Mn)
8.3.1.Overview
8.3.2.Cancer
8.3.3.Infectious Disease
8.3.4.Other Applications
8.4.Asia Pacific mRNA Vaccine and Therapeutics Market, by End User, 2015-2027(US$ Mn)
8.4.1.Overview
8.4.2.Hospitals and Clinics
8.4.3.Research Organizations
8.4.4.Other End Users

9.Latin America
9.1.Latin America mRNA Vaccine and Therapeutics Market, by Country, 2015-2027(US$ Mn)
9.1.1.Brazil
9.1.2.Argentina
9.1.3.Peru
9.1.4.Chile
9.1.5.Colombia
9.1.6.Rest of Latin America
9.2.Latin America mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027(US$ Mn)
9.2.1.Overview
9.2.2.Self-amplifying mRNA-based Vaccines
9.2.3.Conventional Non-Amplifying mRNA-Based Vaccines
9.3.Latin America mRNA Vaccine and Therapeutics Market, by Application, 2015-2027(US$ Mn)
9.3.1.Overview
9.3.2.Cancer
9.3.3.Infectious Disease
9.3.4.Other Applications
9.4.Latin America mRNA Vaccine and Therapeutics Market, by End User, 2015-2027(US$ Mn)
9.4.1.Overview
9.4.2.Hospitals and Clinics
9.4.3.Research Organizations
9.4.4.Other End Users

10.Middle East
10.1.Middle East mRNA Vaccine and Therapeutics Market, by Country, 2015-2027(US$ Mn)
10.1.1.UAE
10.1.2.KSA
10.1.3.Israel
10.1.4.Turkey
10.1.5.Iran
10.1.6.Rest of Middle East
10.2.Middle East mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027(US$ Mn)
10.2.1.Overview
10.2.2.Self-amplifying mRNA-based Vaccines
10.2.3.Conventional Non-Amplifying mRNA-Based Vaccines
10.3.Middle East mRNA Vaccine and Therapeutics Market, by Application, 2015-2027(US$ Mn)
10.3.1.Overview
10.3.2.Cancer
10.3.3.Infectious Disease
10.3.4.Other Applications
10.4.Middle East mRNA Vaccine and Therapeutics Market, by End User, 2015-2027(US$ Mn)
10.4.1.Overview
10.4.2.Hospitals and Clinics
10.4.3.Research Organizations
10.4.4.Other End Users

11.Africa
11.1.Africa mRNA Vaccine and Therapeutics Market, by Country, 2015-2027(US$ Mn)
11.1.1.South Africa
11.1.2.Egypt
11.1.3.Nigeria
11.1.4.Rest of Africa
11.2.Africa mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027(US$ Mn)
11.2.1.Overview
11.2.2.Self-amplifying mRNA-based Vaccines
11.2.3.Conventional Non-Amplifying mRNA-Based Vaccines
11.3.Africa mRNA Vaccine and Therapeutics Market, by Application, 2015-2027(US$ Mn)
11.3.1.Overview
11.3.2.Cancer
11.3.3.Infectious Disease
11.3.4.Other Applications
11.4.Africa mRNA Vaccine and Therapeutics Market, by End User, 2015-2027(US$ Mn)
11.4.1.Overview
11.4.2.Hospitals and Clinics
11.4.3.Research Organizations
11.4.4.Other End Users

12.Global
12.1.Global mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027(US$ Mn)
12.1.1.Overview
12.1.2.Self-amplifying mRNA-based Vaccines
12.1.3.Conventional Non-Amplifying mRNA-Based Vaccines
12.2.Global mRNA Vaccine and Therapeutics Market, by Application, 2015-2027(US$ Mn)
12.2.1.Overview
12.2.2.Cancer
12.2.3.Infectious Disease
12.2.4.Other Applications
12.3.Global mRNA Vaccine and Therapeutics Market, by End User, 2015-2027(US$ Mn)
12.3.1.Overview
12.3.2.Hospitals and Clinics
12.3.3.Research Organizations
12.3.4.Other End Users

13.Company Profiles
13.1.Pfizer Inc.
13.2.Arcturus Therapeutics Inc.
13.3.Moderna Therapeutics Inc
13.4.BioNTech SE
13.5.CureVac AG
13.6.Etherna
13.7.ethris GmbH
13.8.Translate Bio Inc.
13.9.GlaxoSmithKline PLC
13.10.Argos Therapeutics, Inc.
13.11.Sangamo Therapeutics Inc.

List of Figures

FIG. 1 Global mRNA Vaccine and Therapeutics Market: Research Methodology

FIG. 2 Market Size Estimation – Top Down & Bottom up Approach

FIG. 3 Global mRNA Vaccine and Therapeutics Market Segmentation

FIG. 4 Global mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2019 (US$ Mn)

FIG. 5 Global mRNA Vaccine and Therapeutics Market, by Application, 2019 (US$ Mn)

FIG. 6 Global mRNA Vaccine and Therapeutics Market, by End User, 2019 (US$ Mn)

FIG. 7 Global mRNA Vaccine and Therapeutics Market, by Geography, 2019 (US$ Mn)

FIG. 8 Attractive Investment Proposition, by Geography, 2019

FIG. 9 Global Market Positioning of Key mRNA Vaccine and Therapeutics Market Manufacturers, 2019

FIG. 10 Global mRNA Vaccine and Therapeutics Market Value Contribution, By Vaccine Type, 2020 & 2027 (Value %)

FIG. 11 Global mRNA Vaccine and Therapeutics Market, by Self-amplifying mRNA-based Vaccines, Value, 2015-2027 (US$ Mn)

FIG. 12 Global mRNA Vaccine and Therapeutics Market, by Conventional Non-Amplifying mRNA-Based Vaccines, Value, 2015-2027 (US$ Mn)

FIG. 13 Global mRNA Vaccine and Therapeutics Market Value Contribution, By Application, 2020 & 2027 (Value %)

FIG. 14 Global mRNA Vaccine and Therapeutics Market, by Cancer, Value, 2015-2027 (US$ Mn)

FIG. 15 Global mRNA Vaccine and Therapeutics Market, by Infectious Disease, Value, 2015-2027 (US$ Mn)

FIG. 16 Global mRNA Vaccine and Therapeutics Market, by Others, Value, 2015-2027 (US$ Mn)

FIG. 17 Global mRNA Vaccine and Therapeutics Market Value Contribution, By End User, 2020 & 2027 (Value %)

FIG. 18 Global mRNA Vaccine and Therapeutics Market, by Hospitals and Clinics, Value, 2015-2027 (US$ Mn)

FIG. 19 Global mRNA Vaccine and Therapeutics Market, by Research Organizations, Value, 2015-2027 (US$ Mn)

FIG. 20 Global mRNA Vaccine and Therapeutics Market, by Others, Value, 2015-2027 (US$ Mn)

FIG. 21 U.S. mRNA Vaccine and Therapeutics Market, 2015-2027 (US$ Mn)

FIG. 22 Rest of North America mRNA Vaccine and Therapeutics Market, 2015-2027 (US$ Mn)

FIG. 23 U.K. mRNA Vaccine and Therapeutics Market, 2015-2027 (US$ Mn)

FIG. 24 Germany mRNA Vaccine and Therapeutics Market, 2015-2027 (US$ Mn)

FIG. 25 France mRNA Vaccine and Therapeutics Market, 2015-2027 (US$ Mn)

FIG. 26 Rest of Europe mRNA Vaccine and Therapeutics Market, 2015-2027 (US$ Mn)

FIG. 27 Japan mRNA Vaccine and Therapeutics Market, 2015-2027 (US$ Mn)

FIG. 28 China mRNA Vaccine and Therapeutics Market, 2015-2027 (US$ Mn)

FIG. 29 India mRNA Vaccine and Therapeutics Market, 2015-2027 (US$ Mn)

FIG. 30 Rest of Asia Pacific mRNA Vaccine and Therapeutics Market, 2015-2027 (US$ Mn)

FIG. 31 Middle East & Africa mRNA Vaccine and Therapeutics Market, 2015-2027 (US$ Mn)

Latin America mRNA Vaccine and Therapeutics Market, 2015-2027 (US$ Mn)

List of Tables

TABLE 1 Market Snapshot: Global Beauty Devices   (mRNA Vaccine and Therapeutics) Market

TABLE 2 Global mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027 (US$ Mn)

TABLE 3 Global mRNA Vaccine and Therapeutics Market, by Application, 2015-2027 (US$ Mn)

TABLE 4 Global mRNA Vaccine and Therapeutics Market, by End User, 2015-2027 (US$ Mn)

TABLE 5 Global mRNA Vaccine and Therapeutics Market, by Geography, 2015-2027 (US$ Mn)

TABLE 6 North America mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027 (US$ Mn)

TABLE 7 North America mRNA Vaccine and Therapeutics Market, by Application, 2015-2027 (US$ Mn)

TABLE 8 North America mRNA Vaccine and Therapeutics Market, by End User, 2015-2027 (US$ Mn)

TABLE 9 North America mRNA Vaccine and Therapeutics Market, by Country, 2015-2027 (US$ Mn)

TABLE 10 Europe mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027 (US$ Mn)

TABLE 11 Europe mRNA Vaccine and Therapeutics Market, by Application, 2015-2027 (US$ Mn)

TABLE 12 Europe mRNA Vaccine and Therapeutics Market, by End User, 2015-2027 (US$ Mn)

TABLE 13 Europe mRNA Vaccine and Therapeutics Market, by Country/Region, 2015-2027 (US$ Mn)

TABLE 14 Asia Pacific mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027 (US$ Mn)

TABLE 15 AsiaPacific mRNA Vaccine and Therapeutics Market, by Application, 2015-2027 (US$ Mn)

TABLE 16 Asia Pacific mRNA Vaccine and Therapeutics Market, by End User, 2015-2027 (US$ Mn)

TABLE 17 Asia Pacific mRNA Vaccine and Therapeutics Market, by Country/Region, 2015-2027 (US$ Mn)

TABLE 18 Latin America mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027 (US$ Mn)

TABLE 19 Latin America mRNA Vaccine and Therapeutics Market, by Application, 2015-2027 (US$ Mn)

TABLE 20 Latin America mRNA Vaccine and Therapeutics Market, by End User, 2015-2027 (US$ Mn)

TABLE 21 Latin America mRNA Vaccine and Therapeutics Market, by Country/Region, 2015-2027 (US$ Mn)

TABLE 22 Middle East mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027 (US$ Mn)

TABLE 23 Middle East mRNA Vaccine and Therapeutics Market, by Application, 2015-2027 (US$ Mn)

TABLE 24 Middle East mRNA Vaccine and Therapeutics Market, by End User, 2015-2027 (US$ Mn)

TABLE 25 Middle East mRNA Vaccine and Therapeutics Market, by Country/Region, 2015-2027 (US$ Mn)

TABLE 26 Africa mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027 (US$ Mn)

TABLE 27 Africa mRNA Vaccine and Therapeutics Market, by Application, 2015-2027 (US$ Mn)

TABLE 28 Africa mRNA Vaccine and Therapeutics Market, by End User, 2015-2027 (US$ Mn)

TABLE 29 Africa mRNA Vaccine and Therapeutics Market, by Country/Region, 2015-2027 (US$ Mn)

TABLE 30 Pfizer Inc.: Company Snapshot (Company Overview; Vaccine Type Portfolio; Financial Information; Key Developments)

TABLE 31 Arcturus Therapeutics Inc.: Company Snapshot (Company Overview; Vaccine Type Portfolio; Financial Information; Key Developments)

TABLE 32  Moderna Therapeutics Inc: Company Snapshot (Company Overview; Vaccine Type Portfolio; Financial Information; Key Developments)

TABLE 33 BioNTech SE.: Company Snapshot (Company Overview; Vaccine Type Portfolio; Financial Information; Key Developments)

TABLE 34 CureVac AG: Company Snapshot (Company Overview; Vaccine Type Portfolio; Financial Information; Key Developments)

TABLE 35  Etherna: Company Snapshot (Company Overview; Vaccine Type Portfolio; Financial Information; Key Developments

TABLE 36 ethris GmbH: Company Snapshot (Company Overview; Vaccine Type Portfolio; Financial Information; Key Developments

TABLE 37 Translate Bio Inc.: Company Snapshot (Company Overview; Vaccine Type Portfolio; Financial Information; Key Developments

TABLE 38 GlaxoSmithKline PLC: Company Snapshot (Company Overview; Vaccine Type Portfolio; Financial Information; Key Developments

TABLE 39 Argos Therapeutics, Inc.: Company Snapshot (Company Overview; Vaccine Type Portfolio; Financial Information; Key Developments

Sangamo Therapeutics Inc.: Company Snapshot (Company Overview; Vaccine Type Portfolio; Financial Information; Key Developments